Limitations and opportunities of non-invasive liver stiffness measurement in children

Guido Engelmann, Jasmin Quader, Ulrike Teufel, Jens Peter Schenk

Abstract
Changes in liver structure are an important issue in chronic hepatopathies. Until the end of the 20th century, these changes could only be determined by histological analyses of a liver specimen obtained via biopsy. The well-known limitations of this technique (i.e., pain, bleeding and the need for sedation) have precluded its routine use in follow-up of patients with liver diseases. However, the introduction of non-invasive technologies, such as ultrasound and magnetic resonance imaging, for measurement of liver stiffness as an indirect marker of fibrosis has changed this situation. Today, several non-invasive tools are available to physicians to estimate the degree of liver fibrosis by analysing liver stiffness. This review describes the currently available tools for liver stiffness determination that are applicable to follow-up of liver fibrosis/cirrhosis with established clinical use in children, and discusses their features in comparison to the "historical" tools.

Key words: Children; Transient elastography; Liver fibrosis; Liver biopsy

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Non-invasive liver stiffness measurement is a new and helpful tool for assessing liver fibrosis in children, but it cannot yet replace liver biopsy.
INTRODUCTION

Until the end of the 20th century structural changes of the liver could only be determined by histological analyses of a liver specimen obtained by percutaneous liver biopsy. The well-known limitations of this technique (i.e., pain, bleeding and the need for sedation), however, precluded its routine use in follow-up of patients with liver diseases, and it has only been used routinely in studies411. The introduction of non-invasive imaging technologies, such as ultrasound and magnetic resonance imaging, has changed this situation, allowing for measurement of liver stiffness as an indirect marker of fibrosis. Today, several non-invasive tools are available to physicians to estimate the degree of liver fibrosis by analysing liver stiffness.

This review will describe the currently available tools for liver stiffness determination that are applicable to follow-up of liver fibrosis/cirrhosis with established clinical use in paediatric patients (children between 0 and 18-year-old), and discusses their features in comparison to the “historical” tools.

Liver fibrosis is a dynamic reaction of the healthy liver towards chronic cell injury3. It is frequently observed in patients with chronic liver disease, regardless of aetiology3 and patient age. Structural changes of liver architecture usually appear slowly, within years or decades, and accompanied by a continual development from low-grade fibrosis to liver cirrhosis. Liver cirrhosis, itself, represents the end-stage of fibrotic liver diseases.

Development of fibrosis leads to an increase in liver stiffness, detectable by non-invasive methods. Progression from liver fibrosis to cirrhosis may be preventable, if the fibrosis is detected early in the course. Examples of preventable fibrosing liver diseases are hepatitis B or hepatitis C infections4,5, liver transplantation6 and Wilson’ disease. For other fibrosis aetiologies, a close follow-up is recommended to detect changes in liver structure in a timely manner and to determine the disease course. This holds true for post-liver-transplant patients and patients with autoimmune liver diseases. Today, histology is the gold standard for the diagnosis of liver fibrosis.

Liver biopsy

Liver biopsy remains the method of choice for clarification of the aetiology of hepatopathies. It has the advantage of obtaining direct information, not only on the degree of fibrosis but also on the presence of inflammation, necrosis, steatosis, and iron or copper deposits. However, the histopathologic examination of a liver specimen also has limitations. Studies have clearly indicated that liver biopsy is prone to sampling errors and may underestimate the amount of liver fibrosis. As such, cirrhosis could be missed on a percutaneous liver biopsy, reportedly affecting an estimated 30% of cases7,8. Liver biopsy has further technical limitations. There is a small risk of clinically relevant bleeding (0.3%) and mortality due to the intervention, shown to affect 0.04%-0.07% in a large case series9. In a paediatric series, major complications occurred in 1.5% and minor complications in 25% of 275 liver biopsies10. Another drawback of this method is the size of the specimen obtained8. A single liver biopsy reportedly has a 20%-30% chance of missing the relevant area of interest, thereby underestimating liver diseases11. Paediatric patients have an additional risk due to the need of sedation for the biopsy procedure. Therefore, in clinical practice liver histology is almost exclusively used for diagnoses and only in certain settings, such as liver transplantation, and for therapy control11-12.

On the other hand, liver biopsy has some clear advantages. A recent study of a cohort of patients with either histologically-proven non-alcoholic steatohepatitis (NASH) or non-alcoholic fatty liver disease (NAFLD) showed that outcome (i.e., death, liver transplantation or severe liver disease) was directly dependent upon the degree of fibroses13. Another recent study by Mann et al14 demonstrated an association of portal inflammation, metabolic syndrome and fibrosis in 430 obese children. These findings support the current tenet that portal inflammation and exact degree of fibrosis are best determined by liver biopsy.

Histological assessment of liver biopsy

The liver biopsy specimen is recommended to have length of at least 10 mm and width of at least 1 mm (obtained with > 18 gauge needle)15. Several histological scoring systems have been established for grading (necroinflammatory activity) and staging (fibrosis) of structural liver damage in patients16. The Desmet score17 is used to evaluate adult hepatitis C patients, and the METAVIR18,19 and Ishak score20 are used in cases of chronic viral hepatitis (B and C). The SSS-score of Chevallier21 was developed to quantify fibrosis irrespective of the underlying disease. Some of these scores have been evaluated in children (Table 1), and a detailed break-down of each (in children and adults) is provided below: (1) the METAVIR score18 assesses fibrosis qualitatively on a 0-4 scale, with F0 indicating absence of fibrosis, F1 indicating portal fibrosis without septa, F2 indicating portal fibrosis with a few septa, F3 indicating architectural distortion with numerous septa without cirrhosis, and F4 indicating cirrhosis. This score has been used to evaluate adult patients with hepatitis B and C20 and paediatric patients after liver transplantation21, biliary atresia22, intestinal failure23 and total parenteral nutrition24; (2) the grading score of Ishak et al20 assesses fibrosis qualitatively on a 0-6 scale. The Ishak score has been used in paediatric populations with various liver diseases, and including children after liver transplantation20 or cardiovascular surgery27; (3) the grading score of Desmet et al17 assesses fibrosis qualitatively on a 0-4 scale, with F0 indicating absence of fibrosis, F1 indicating portal fibrosis, F2 indicating fibrosis with septa without distortion of the liver architecture, F3 indicating septal fibrosis with severe
distortion of the liver architecture, and F4 indicating cirrhosis. It has been used to evaluate adult patients with chronic hepatitis C\[^{28}\], and (4) the semi-quantitative severity score of Chevalier \ et al\[^{21}\] has been used in children\[^{29}\] and adults with hepatitis B\[^{30}\] and C\[^{31}\].

**Aminotransferases**

Numerous attempts have been made to determine liver fibrosis by non-invasive means. One of the oldest measurement of serum aminotransferases, which remains the most widely used, and convenient, tool to measure liver cell integrity. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are inexpensive laboratory values. They can be easily obtained from a patient and are stable in serum specimen. ALT, especially, is highly liver specific.

Unfortunately, aminotransferases poorly reflect the stage of liver fibrosis or cirrhosis. If they are elevated, a more detailed examination of the liver is obligatory. But, ALT and AST may even be normal or only slightly elevated in fibrotic or cirrhotic liver diseases. The positive predictive value of aminotransferases for NAFLD or NASH is low. In a series of 222 patients with histologically-proven NAFLD, 37% of the patients with advanced fibrosis or NASH presented with normal ALT levels. This phenomenon was also recently demonstrated in children, in a study of paediatric cases of NAFLD conducted by Molleston \ et al\[^{32}\].

Aminotransferases may serve as a first screening tool for detection of fibrosis, but even normal levels of aminotransferases do not exclude severe liver disease with changes in liver structure. Some of the techniques that have been developed to identify NAFLD in adult patients have been tested in children, including the AST to platelet ratio index (APRI) score, the NAFLD fibrosis score\[^{33}\] and the Fibrosis-4 index score. Yet, recent data have indicated that only the APRI score and the paediatric NAFLD fibrosis score reliably reflect fibrotic changes of the liver. Alkhouri \ et al\[^{34}\] have developed and published a new paediatric NAFLD fibrosis score based on a model using ALT, alkaline phosphatase, platelet counts and gamma-glutamyl transferase, and demonstrated its predictive ability of fibrosis as good.

Collectively, these tests are reliable in detecting severe fibrosis or cirrhosis (grade 2 or greater for the Desmet score). Thus, while they can reliably show if the patient suffers from a change in liver structure they cannot reliably predict the exact degree of fibrosis.

**SONOELASTOGRAPHY**

**Transient elastography**

Transient elastography (TE) is a technique based on the measurement of the velocity of a shear wave that is induced to the liver by a mechanical impulse. To apply that impulse to the liver, the probe has to be pressed onto the skin with a certain force, and the thoracic wall prevents the liver from being compressed by the probe. Therefore, TE can only be measured reliably in the right lobe of the liver and not in other organs or in other parts of the liver.

The velocity of the shear wave is directly proportional to the stiffness of the liver. Stiffness mainly depends on the amount of fibrotic material in the liver. Therefore, liver elasticity is measured in kilopascal (kPa) and liver stiffness increases with liver fibrosis. The probe is placed in the 7\[^{th}\] or 8\[^{th}\] intercostal space in the right ventral axillary line. The patient lies in supine position, with the right arm in maximal abduction. This technique has been described in detail elsewhere\[^{35}\]. A mechanical impulse of 50 Hz induces an elastic shear wave that passes through the liver tissue. The speed of this wave is measured via ultrasound. For more detailed information on the basic physical principle, the Young Modules, see Frullo \ et al\[^{36}\].

TE reliably detects liver fibrosis, as demonstrated in numerous studies and meta-analyses comparing the technology to liver biopsy\[^{35-42}\]. The median liver stiffness in adults varies between 4.4 and 5.5\[^{43,44}\]. In addition, there is evidence that stiffness is greater in males, increases with body mass index in adult patients, and tends to increase with age but not to a statistically significant extent\[^{43}\]. In children, the median liver stiffness significantly rises with age, starting with 4.4 in preschool children and rising to 5.1 in pubertal children. Liver stiffness in children has also been shown to differ according to sex, with girls showing significantly less (4.7) than boys (5.6)\[^{46}\]. In split liver transplants of left liver, which is the main transplantation technique used in infants, toddlers and preschool children, liver stiffness measurement cannot be used because it is technically performable only in the right liver lobe (as detailed above). A clinical example of TE use in a paediatric patient is presented in Figure 1.

Introduction of the small TE-probe that is also suitable for use with infants and very young children has made TE possible for every age group. But liver stiffness measurement can only be performed in a patient that is laying calmly in supine position. This is usually not an

---

**Table 1 Comparison of the 4 main histological scoring systems used in the evaluation of fibrosis in paediatric liver diseases today**

| Scoring system | Staging | Evaluated in adults with | Evaluated in children with |
|----------------|---------|--------------------------|---------------------------|
| METAVIR        | F0-F4   | Hepatitis B and C        | Biliary atresia, intestinal failure, total parenteral nutrition and post-liver transplantation |
| Ishak          | F0-F6   | Hepatitis B and C        | Post-liver transplantation and after cardiovascular surgery |
| Desmet         | F0-F4   | Hepatitis C              | No                        |
| SSS-score      | 0- > 15 | Hepatitis B and C        | Hepatitis B               |
attainable state in toddlers without sedation. Therefore, the problem of invalid liver stiffness measurement due to moving and crying of the patients makes this method questionable in infants.

Another general drawback of this method is the price. The technique is reliant on hardware that ultrasound machines do not come equipped with normally. Therefore, an extra-device is required to accompany the ultrasound machine and this produces extra-costs of more than 50000 Euros. Finally, the capacity for integrated measurement in B-mode ultrasound images is not yet available.

Findings from a recent Cochrane analysis of adult patients with alcoholic liver disease led to the recommendation of TE as a useful tool to exclude fibrosis and, in cases of liver stiffness measurement above 12.5 kPa, to suggest cirrhosis. These data, however, still have to be confirmed in further studies[46], especially for their applicability to the paediatric age group. It is well accepted that TE enables the investigator to clearly exclude severe changes in liver architecture, but it remains a matter of debate whether TE can also enable clear staging of fibrosis. As such, TE is routinely used to assess liver fibrosis in adult patients with chronic hepatitis C, and this use is confirmed in the EASL Clinical Practice Guidelines 2011[47]. With the increasing application of TE in children with viral hepatitis, however, TE has the capability to gain more relevance for detection of liver fibrosis.

Acoustic radiation force impulse
Acoustic radiation force impulse (ARFI) is a point shear wave elastography that measures tissue elasticity independent of an external mechanical impulse to the tissue. Therefore, this method is not only useful for liver stiffness measurement but also for determination of changes in stiffness of the spleen[48], testis[49], thyroid[50], breast[51], placenta[52], pancreas in chronic pancreatitis[53] and transplanted kidney[54]. The technique is based on an acoustic impulse and measurement of the speed of the shear wave induced by it; results are displayed in m/s. The stiffer the organ, the faster the shear wave.

The ARFI method has two advantages. First, it can be performed by an additional technical tool for a high-end ultrasound system, providing integrated B-mode images. Second, the tissue is not compressed by the probe, as in TE. Compression itself causes changes in stiffness, and this feature of ARFI enables measurement of stiffness in numerous tissues. Many studies have shown the reliability and reproducibility of this technique in adult patients[55] and in children[56]. The correlation of ARFI and fibrosis is in a good range[57], comparable to that of TE[58], and control-values have been established for children[56,59] and adults[16] (Table 2). Moreover, ARFI was demonstrated as effective in paediatric patient groups with biliary atresia or severe fibrosis[60,61] and in follow-up after liver transplantation[52]. A clinical example of ARFI use in a paediatric patient is presented in Figure 2.

Children with biliary atresia could gain particular benefit from non-invasive examinations for assessment of timing of liver transplantation after Kasai-portoenterostomy[62,64]. According to METAVIR or SSS-score, ARFI shows overlap of shear wave velocity values in different fibrosis stages, as shown in the study by Hanquinet et al[65]. ARFI might offer diagnostic advantages over B-mode imaging in terms of combining stiffness measurement with sonomorphological parameters as the qualitative sonomorphological aspect becomes

Figure 1 Transient elastography findings for a 10-year-old female suffering from Wilson's disease. The patient’s brother had previously developed acute liver failure, which triggered routine monitoring of the patient thereafter. The patient was clinically completely healthy. The transient elastography shows 9.3 kPa, which is above the 6.5 kPa upper limit of normal. Histology findings for the patient showed the liver to be cirrhotic.

| Information | min | mm |
|-------------|-----|----|
|              | 0.0 | 0.0|
|              | 20.0| 20.0|
|              | 40.0| 40.0|
|              | 60.0| 60.0|

Table 2. Typical ARFI values in children and adults.
Table 2  Control and normal values of non-invasive liver stiffness measurement

|                  | Normal values (ULN is defined as mean + 1.64 SD)                  |
|------------------|---------------------------------------------------------------|
|                  | Children                                                      |
|                  | Adults                                                        |
| TE               | ULN: 6.47 kPa (36)                                            | 8.3/7.83 (m/f) (36)                                           |
| RTE              | Median: 106 a.u. (37)                                          | 127 a.u. (37)                                                 |
|                  | Mean: 2.71 kPa (34)                                           | 3.45 kPa (34)                                                 |
|                  | -2.93 kPa (37)                                                |                                                               |
| ARFI             | ULN: 1.39 m/s (mean + 1.64 SD) (38,39)                        | 1.35 m/s (41)                                                 |

Normal values are defined as mean + 1.64 times SD, while control values are expressed as mean. ARFI: Acoustic radiation force impulse; RTE: Real-time tissue elastography; TE: Transient elastography; ULN: Upper limit of normal.

Figure 2  Acoustic radiation force impulse measurement of the liver in a 16-year-old female patient with cystic fibrosis. Hyperechoic liver parenchyma with irregular liver surface in fibrotic liver parenchyma was revealed. The shear wave velocity was 2.3-3.82 m/s in multiple measurements, significantly above normal values. The same patient had undergone a Fibroscan and the results showed a stiffness of 21.3 ± 2.5 kPa. Six months previously, another Fibroscan had shown a value of 20.4 ± 2.8 kPa.

Figure 3  Real-time tissue elastography in a normal and cirrhotic liver. A: RTE with a normal strain histogram (mean: 113.3 a.u.; %AREA: 10%) in a 8-year-old female patient with cystic fibrosis and nearly normal liver structure; B: RTE with pathological strain histogram in a 6-year-old female patient with tyrosinemia type 1 and liver cirrhosis with small nodules. The mean value was 99.9, and the peak of histogram shifted to the left to lower values of the mean. The percentage of stiffer areas (colour-coded in blue; %AREA) increased up to 23.6%. This histogram is more flattened in comparison to the normal strain histogram. RTE: Real-time tissue elastography.

Quantitative[61]. This makes comparison in patients easier.

Similar to TE, increased application of ARFI in children could lead to an implementation of this type of measurement in the routine clinical work flow, especially for patients with specific paediatric diseases, such as cystic fibrosis or biliary atresia.

Real-time tissue elastography

Real-time tissue elastography (RTE) examinations can be performed with an ultrasound device and a standard linear transducer[66]. The RTE software captures images of tissue motions caused by heartbeats or respiration. These images are then transferred into colour-coded plane and the system calculates a histogram of strain elasticity values of the matrix in arbitrary units (a.u.), ranging from 0 to 255[67]. The method can be performed without extra-hardware, but data on the value of this method in children are scarce. Morikawa et al[67]analysed RTE in 101 adult patients with hepatitis c and found a good correlation of the RTE values with the histologic grading of fibroses. In contrast, data obtained from children in another study[60]showed only a moderate correlation, and it was concluded that RTE could not be recommended for a clear differentiation of fibrosis stages while the difference between stage IV fibrosis and normal liver tissue or stage I fibrosis was significant.

Other studies of adult patients[60]have concentrated on the elastic or fibrosis index values, which have not been adequately studied in the paediatric age group. In a meta-analysis of RTE conducted by Kobayashi et al[70], the authors concluded that RTE has low accuracy for detecting any stage of fibrosis. Today, we would not recommend the use of single statistical parameters as the mean elasticity value of strain histogram or %AREA in children alone to predict the histological fibrosis stage. Differentiation of high fibrosis stages to normal tissue is possible, but application in young infants can be...
difficult. Clinical examples of RTE use in two paediatric patients are presented in Figure 3.

Further studies on the use of the elastic index in paediatric patients should be conducted. High fibrosis stages can be differentiated from low fibrosis stages, but no clinical recommendations exist as of yet.

**MR-elastography**

MR-elastography (MRE) is an elastography technique using an acoustic impulse to produce a shear wave. The impulse is produced by an audio subwoofer and subsequently transmitted to the liver via a connecting-tube that is placed on the skin of the patient. Then, the shear wave induced by this acoustic impulse is measured and stiffness is calculated in kPa\(^{[71]}\). Studies of MRE in adult patients with hepatitis C have shown good relation of MRE-measured liver stiffness, as compared to Child-Pugh score\(^{[72]}\). In another study of adult patients with cystic fibrosis\(^{[73]}\) the liver stiffness measurement was shown to correlate well with serum levels of aminotransferases and also with ultrasound findings, but there were insufficient data to make any conclusions regarding histopathologic changes.

A new and promising application of MRE involves the differentiation of NASH from NAFLD. Both diseases can occur in obese patients, but there is yet no non-invasive method capable of distinguishing between the two. Patients with NASH develop cirrhosis in 10% of cases, while patients with NAFLD do not. Neither aminotransferases\(^{[72]}\) nor ultrasound can differentiate these two diseases. Recent studies have suggested that MRE might be able to reliably determine the presence of NASH in an obese patient\(^{[74]}\). Future studies may prove that MRE, therefore, is useful, even in clinical analysis of obese patients, for defining relevant end-points.

**DISCUSSION**

ARFI does not replace liver biopsy for staging of liver fibroses or cirrhosis, neither do TE, RTE or MRE\(^{[75,76]}\). The limitations of these non-invasive techniques are low specificity and high cost, the latter being especially relevant for TE.

Liver structure changes can be excluded by each of these non-invasive techniques, with an acceptable sensitivity but an unacceptable low specificity. TE, ARFI and MRE have the potential to exclude severe liver structure changes. For RTE, however, the data are conflicting and do not support a recommendation; certainly, further studies are necessary. For diagnosing liver disease, none of these non-invasive techniques is useful. But, in many patients, the ethology is quite clear due to readily assessable clinical or laboratory aspects, such as the presence of obesity, chronic viral hepatitis or alpha-1 antitrypsin deficiency. In cases of the patient being post-liver transplantation or with an already-obtained liver biopsy, the analysis of liver structure changes is of greater importance.

A possible diagnostic approach to patients with liver disease in 2016 is to first perform clinical examinations to obtain anthropometric data, ultrasound images and standard laboratory measures. If then there is evidence for liver disease, ARFI or TE should be performed. If those findings then suggest liver structure changes, a biopsy should be obtained in any case. If the findings suggest normal liver structure, the biopsy may be delayed and further laboratory studies may be performed first. If there is no change in aminotransferase levels after 6 mo, a liver biopsy should be performed. Non-invasive liver stiffness measurement can be used for follow-up after liver biopsy if the stage of fibrosis has been determined based on histopathological criteria\(^{[77]}\).

In patients with obesity, MRE possibly offers a new approach by which to define patients at risk for NASH or even to diagnose NASH in obese patients. Therefore, in the setting of an obese patient, MRE presents a real advantage over the classical methods of hepatology and future studies will show if this promising technique is suited to becoming part of the routine diagnostic workup in obese patients early in their clinical course and also in follow-up.

**REFERENCES**

1. Valamanchil K, Saadeh S, Klintmalm GB, Jennings LW, Davis GL. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. Liver Transpl 2010; 16: 431-439 [PMID: 20373454 DOI: 10.1002/lt.22004]
2. Schuppan D, Kim YO. Evolving therapies for liver fibrosis. J Clin Invest 2013; 123: 1887-1901 [PMID: 23635787 DOI: 10.1172/ JC116028]
3. Tanner MS. Mechanisms of liver injury relevant to pediatric hepatology. Crit Rev Clin Lab Sci 2002; 39: 1-61 [PMID: 11890207 DOI: 10.1080/10408360290795439]
4. Manns M, Pol S, Jacobson IM, Marcellin P, Gordon SC, Peng CY, Chang TT, Everson GT, Heo J, Gerken G, Yoffe B, Towner WJ, Bourliere M, Metivier S, Chu CJ, Sievert W, Bronowicki JP, Thabut D, Lee YJ, Kao JH, McPhee F, Kopti J, Mendez P, Linaberry M, Hughes E, Noviello S. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 2014; 384: 1597-1605 [PMID: 25078304 DOI: 10.1016/S0140-6736(14)61059-X]
5. Bernath S, Yagmur E, Schuppan D, Sprinzl MF, Zimmermann A, Schad A, Kittner JM, Weyer V, Knapstein J, Schattenberg JM, Wöns MA, Galle PR, Zimmermann T. Early changes in dynamic biomarkers of liver fibrosis in hepatitis C virus-infected patients treated with sofosbuvir. Dig Liver Dis 2016; 48: 291-297 [PMID: 26514736 DOI: 10.1016/j.dld.2015.09.015]
6. Crespo G, Castro-Narro G, García-Juárez I, Benitez C, Ruiz P, Sastre L, Colmenero J, Miquel R, Sánchez-Fueyo A, Forns X, Navasa M. Usefulness of liver stiffness measurement during acute cellular rejection in liver transplantation. Liver Transpl 2016; 22: 298-304 [PMID: 26690794 DOI: 10.1002/hep.24376]
7. Ponichlik J, Bernstein DE, Reddy KR, Jeffers LJ, Coelho-Little MF, Civantos F, Schiff ER. The role of laparoscopy in the diagnosis of cirrhosis. Gastrointest Endosc 1996; 43: 568-571 [PMID: 8781934]
8. Maharaj B, Maharaj RJ, Leary WP, Cooppan RM, Naran AD, Pirie D, Pudifin DJ. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1986; 1: 523-525 [PMID: 2869260]
9. Atwell TD, Smith RL, Hesley GK, Callstrom MR, Schleck CD, Harmsen WS, Charboneau JW, Welch TJ. Incidence of bleeding
after 15,181 percutaneous biopsies and the role of aspartate aminotransferase to platelet ratio index correlates with hepatic cirrhosis but not with fibrosis in pediatric patients with intestinal failure. J Pediatr Gastroenterol Nutr 2013; 57: 367-371 [PMID: 23666459 DOI: 10.1097/MPG.0b013e3182996db]

25 Mutanen A, Lohi J, Heikkilä P, Koivusalo A, Rintala RJ, Pakarinen MP. Persistent abnormal liver fibrosis after weaning off parental nutrition in pediatric intestinal failure. Hepatology 2013; 58: 729-738 [PMID: 23460496 DOI: 10.1002/hep.26360]

26 Venturi C, Sempoux C, Bueno J, Ferreres Pinas JC, Bourdeaux C, Abarca-Quinones J, Rahier J, Reding R. Novel histologic scoring system for long-term alfagrost fibrosis after liver transplantation in children. Am J Transplant 2012; 12: 2986-2996 [PMID: 22882699 DOI: 10.1111/j.1600-6143.2012.04210.x]

27 Schwartz MC, Sullivan L, Cohen MS, Russo P, John AS, Guo R, Guttenberg M, Rand EB. Hepatic pathology may develop before the Fontan operation in children with functional single ventricle: an autopsy study. J Thorac Cardiovasc Surg 2012; 143: 904-909 [PMID: 21955477 DOI: 10.1016/j.jtsa.2011.08.038]

28 Deldadetska JK, Rassidakis G, Tassopoulos NC, Papathereodiris GV, Smyrniot F, Vafiadis I. Histopathology of chronic hepatitis C in relation to epidemiological factors. J Hepatol 1996; 24: 27-32 [PMID: 8384021]

29 Li ZX, He Y, Wu J, Liang DM, Zhang BL, Yang H, Wang LL, Ma Y, Wei KL. Noninvasive evaluation of hepatic fibrosis in children with infant hepatitis syndrome. World J Gastroenterol 2006; 12: 7155-7160 [PMID: 17131478]

30 ter Borg F, ten Kate FJ, Cuypers HT, Leentvaar-Kuijpers A, Oosting J, Wertheim-van Dillen PM, Honkoop P, Pasch MC, de Man RA, van Hattum J, Chamuleau RA, Tytgat GN, Jones EA. A survey of liver pathology in needle biopsies from HBsAg and anti-HBe positive individuals. J Clin Pathol 2000; 53: 541-548 [PMID: 10961179]

31 Zaitoun AM, Al Mardini H, Awad S, Ukabam S, Makadisi S, Record CO. Quantitative assessment of fibrosis and steatosis in liver biopsies from patients with chronic hepatitis C. J Clin Pathol 2001; 54: 461-465 [PMID: 11376020]

32 Mollen JP, Schwinmer JB, Yates KP, Murray RF, Cunnings OW, Lavine JE, Brunt EM, Scheimann AO, Unalp-Arida A. Histological abnormalities in children with nonalcoholic fatty liver disease and normal or mildly elevated alanine aminotransferase levels. J Pediatr 2014; 164: 707-713.e3 [PMID: 24360992 DOI: 10.1016/j.peds.2013.10.071]

33 Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Therneau TM, Day CP. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-854 [PMID: 17395809 DOI: 10.1002/hep.21946]

34 Alkhouri N, Manoos S, Giammara P, Liceardo D, Lopez R, Nobili V. The development of the pediatric NAFLD fibrosis score (PNFS) to predict the presence of advanced fibrosis in children with nonalcoholic fatty liver disease. PLoS One 2014; 9: e104558 [PMID: 25121514 DOI: 10.1371/journal.pone.0104558]

35 Sandrin L, Fourquet B, Hasuqenof YM, Jot S, Fournier C, Mal F, Christidis C, Ziol M, Poulet B, Kazemi F, Beaugrand M, Palau R. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasonad Med Biol 2003; 29: 1705-1713 [PMID: 14698338]

36 Frullo N, Trillard H. Ultrasonic elastography in liver. Diagn Interv Imaging 2013; 94: 515-534 [PMID: 23623211 DOI: 10.1016/j.diii.2012.03.005]

37 Yeshua H, Oren R. Non invasive assessment of liver fibrosis. Ann Transplant 2008; 13: 5-11 [PMID: 18566553]

38 Castella L, Foroni X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48: 835-847 [PMID: 18334275 DOI: 10.1016/j.jhep.2008.02.008]

39 Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, de Ledinghen V, Marcellin P, Duhemes D, Trinchet JC, Beaugrand M. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41: 48-54 [PMID: 15690481 DOI: 10.1002/hep.20506]
with chronic hepatitis C. J Gastroenterol 2011; 46: 350-358 [PMID: 20697747 DOI: 10.1007/s00535-010-0301-x]

Schlenk JP, Flechtenmacher C, Sakka SE, Teufel U, Engelmann G. Real-time tissue elastography (RTE) for noninvasive evaluation of fibrosis in liver diseases in children in comparison to liver biopsy. J Med Ultrason (2001) 2014; 41: 455-462 [PMID: 27278026 DOI: 10.1007/s10396-014-0542-z]

Tatsumi C, Kudo M, Ueshima K, Kitai S, Ishikawa E, Yada N, Hagiwara S, Inoue T, Minami Y, Chung H, Maekawa K, Fujimoto K, Kato M, Tonomura A, Mitake T, Shiina T. Non-invasive evaluation of hepatic fibrosis for type C chronic hepatitis. Intervirology 2010; 53: 76-81 [PMID: 20698346 DOI: 10.1159/000252789]

Kobayashi K, Nakao H, Nishiyama T, Lin Y, Kikuchi S, Kobayashi Y, Yamamoto T, Ishii N, Ohashi T, Satoh K, Nakade Y, Ito K, Yoneda M. Diagnostic accuracy of real-time tissue elastography for the staging of liver fibrosis: a meta-analysis. Eur Radiol 2015; 25: 230-238 [PMID: 25149296 DOI: 10.1007/s00330-014-3364-x]

Binkovitz LA, El-Youssef M, Glaser KJ, Yin M, Binkovitz AK, Ehman RL. Pediatric MR elastography of hepatic fibrosis: principles, technique and early clinical experience. Pediatr Radiol 2012; 42: 402-409 [PMID: 22120578 DOI: 10.1007/s00247-011-2298-6]

Takamura T, Motosugi U, Ichikawa S, Sano K, Morisaka H, Ichikawa T, Enomoto N, Onishi H. Usefulness of MR elastography for detecting clinical progression of cirrhosis from child-pugh class A to B in patients with type C viral hepatitis. J Magn Reson Imaging 2016; 44: 715-722 [PMID: 26929192 DOI: 10.1002/jmri.25182]

Lemaître C, Dominique S, Billoud E, Eliacher M, Montialoux H, Quillard M, Riachi G, Koning E, Morisse-Pradier H, Savoye G, Savoye-Collet G, Garcia O. Relevance of 3D Cholangiography and Transient Elastography to Assess Cystic Fibrosis-Associated Liver Disease? Can Respir J 2016; 2016: 4592702 [PMID: 27445541 DOI: 10.1155/2016/4592702]

Dulai PS, Sirlin CB, Loomba R. MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice. J Hepatol 2016; 65: 1006-1016 [PMID: 27312947 DOI: 10.1016/j.jhep.2016.06.005]

de Alwis NM, Anstee QM, Day CP. How to Diagnose Nonalcoholic Fatty Liver Disease. Dig Dis 2016; 34 Suppl 1: 19-26 [PMID: 27547937 DOI: 10.1159/000447277]

Mansoor S, Colley E, Alkhouri N. A comprehensive review of noninvasive liver fibrosis tests in pediatric nonalcoholic fatty liver disease. Curr Gastroenterol Rep 2015; 17: 23 [PMID: 26031832 DOI: 10.1007/s11894-015-0447-3]

Engelmann G et al. Liver stiffness measurement in children
